JPMorgan, Deutsche Bank, and RBC Capital reiterated their confidence in Eli Lilly’s leadership within the expanding obesity treatment market.
The investment banks cited a strong portfolio and superior drug efficacy as primary drivers for the company’s competitive advantage. Recent clinical trial results for orforglipron, an oral GLP-1 candidate, further bolstered institutional sentiment.
Updated bank analyses include price targets that suggest significant upside potential for the stock. This institutional backing follows recent clinical trial setbacks for primary competitor Novo Nordisk. The contrast in pipeline performance solidifies Eli Lilly’s position as the frontrunner in the lucrative weight-loss therapeutic area.